EYPT: EyePoint Pharmaceuticals, Inc.
About
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Current Value
$9.141 Year Return
Current Value
$9.141 Year Return
Key Details
Market Cap
$492.90M
P/E Ratio
-4.59
1Y Stock Return
50.49%
1Y Revenue Growth
7.50%
Dividend Yield
0.00%
Price to Book
2.3
Strategies that include EYPT
Stock's related to EYPT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| QXO | 72.62% | $6.51B | -35.95% | 0.00% |
| CVM | 46.30% | $41.17M | -73.98% | 0.00% |
| FUN | 46.22% | $4.60B | -16.51% | 0.00% |
| SAIC | 46.10% | $5.92B | +3.71% | 1.24% |
| OCUL | 45.25% | $1.40B | +307.31% | 0.00% |
| CVGW | 41.71% | $482.42M | +14.35% | 1.86% |
| NHC | 41.14% | $1.92B | +61.10% | 1.92% |
| CCSI | 36.26% | $451.51M | +3.04% | 0.00% |
| PAHC | 35.20% | $961.96M | +131.93% | 2.04% |
| FBIO | 33.62% | $43.83M | -27.73% | 0.00% |
| PRPL | 33.57% | $91.37M | +7.08% | 0.00% |
| AQB | 33.49% | $3.78M | -37.77% | 0.00% |
| ALT | 32.19% | $531.30M | +194.09% | 0.00% |
| IBN | 29.56% | $104.98B | +33.69% | 0.80% |
| ALDX | 28.79% | $294.18M | +102.46% | 0.00% |
| SUNS | 28.15% | $105.89M | +35.31% | 1.37% |
| SEG | 28.12% | $319.72M | +12.41% | 0.00% |
| BBWI | 26.35% | $6.67B | +2.60% | 1.99% |
| AVXL | 26.16% | $698.71M | +22.62% | 0.00% |
| RCKT | 26.13% | $1.20B | -39.83% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AVAL | -<0.01% | $791.37M | -4.11% | 7.14% |
| IREN | -<0.01% | $1.96B | +262.72% | 0.00% |
| BHP | 0.01% | $133.61B | -15.74% | 5.55% |
| NTR | 0.01% | $22.48B | -19.05% | 4.73% |
| GOOGL | 0.04% | $2.18T | +30.04% | 0.23% |
| SSL | -0.05% | $1.68B | +20.68% | 1.04% |
| BTU | 0.08% | $3.23B | +14.05% | 1.13% |
| LYB | 0.09% | $26.70B | -14.08% | 6.30% |
| GOOG | -0.10% | $2.20T | +29.55% | 0.22% |
| ETR | 0.11% | $32.14B | +49.00% | 3.05% |
| EH | 0.11% | $689.36M | +1.82% | 0.00% |
| RGLD | 0.11% | $9.72B | +27.40% | 1.09% |
| MBI | -0.12% | $335.78M | +105.79% | 0.00% |
| FICO | -0.13% | $55.62B | +116.55% | 0.00% |
| MUFG | -0.13% | $138.35B | +39.37% | 1.09% |
| PAC | -0.14% | $8.16B | +31.59% | 0.00% |
| FLEX | -0.14% | $14.48B | +96.03% | 0.00% |
| MRO | 0.14% | $16.08B | +13.59% | 1.53% |
| PX | 0.15% | $1.38B | +31.13% | 1.10% |
| CCCS | -0.15% | $7.37B | +2.97% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALK | -30.86% | $6.74B | +44.79% | 0.00% |
| NOK | -21.73% | $22.63B | +17.56% | 3.29% |
| WLKP | -20.06% | $796.39M | +4.00% | 8.34% |
| GYRE | -19.51% | $1.21B | +1.49% | 0.00% |
| LNG | -18.44% | $49.37B | +24.99% | 0.82% |
| MNSO | -15.30% | $5.45B | -28.63% | 1.56% |
| BSM | -13.16% | $3.17B | -13.01% | 10.65% |
| TPL | -12.97% | $32.63B | +163.13% | 0.64% |
| PLTR | -12.64% | $143.47B | +218.08% | 0.00% |
| AMH | -12.43% | $13.89B | +4.91% | 2.67% |
| MSDL | -12.20% | $1.83B | +0.66% | 7.26% |
| RNR | -11.50% | $13.74B | +23.09% | 0.58% |
| CF | -10.17% | $15.23B | +14.45% | 2.28% |
| CEF | -9.98% | - | - | 0.00% |
| EQNR | -9.78% | $64.72B | -22.63% | 5.56% |
| EVRG | -9.75% | $14.71B | +27.45% | 4.01% |
| NERV | -9.66% | $14.69M | -58.00% | 0.00% |
| EG | -9.65% | $15.92B | -8.98% | 2.02% |
| USM | -9.57% | $5.35B | +41.82% | 0.00% |
| PHYS | -9.25% | - | - | 0.00% |
ETF's related to EYPT
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| RSPA | 44.12% | $273.87M | 0% |
| EFAA | 33.87% | $117.38M | 0% |
| XPH | 30.81% | $157.87M | 0.35% |
| XTN | 30.76% | $266.48M | 0.35% |
| QQA | 30.67% | $135.01M | 0% |
| JETS | 25.72% | $1.07B | 0.6% |
| PTH | 25.59% | $143.31M | 0.6% |
| IWC | 24.99% | $933.99M | 0.6% |
| PBE | 24.37% | $258.53M | 0.58% |
| XBI | 24.27% | $6.58B | 0.35% |
| CALF | 23.76% | $8.93B | 0.59% |
| IJT | 23.30% | $6.64B | 0.18% |
| XSLV | 23.10% | $322.27M | 0.25% |
| ISPY | 22.96% | $370.11M | 0.55% |
| SLYG | 22.82% | $3.69B | 0.15% |
| SPSM | 22.76% | $12.72B | 0.03% |
| IJR | 22.75% | $90.05B | 0.06% |
| IWM | 22.65% | $75.73B | 0.19% |
| FYX | 22.65% | $959.00M | 0.6% |
| VTWO | 22.63% | $12.38B | 0.1% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GREK | -0.02% | $180.76M | 0.57% |
| ICSH | 0.02% | $5.57B | 0.08% |
| XONE | -0.03% | $548.88M | 0.03% |
| COMT | 0.05% | $829.06M | 0.48% |
| FIXD | -0.06% | $5.51B | 0.65% |
| IBDT | -0.11% | $2.36B | 0.1% |
| PICK | 0.23% | $856.23M | 0.39% |
| IBDR | 0.28% | $2.93B | 0.1% |
| PREF | 0.31% | $999.92M | 0.55% |
| SMMU | 0.33% | $624.12M | 0.35% |
| SCHP | 0.34% | $11.70B | 0.03% |
| MNA | -0.36% | $220.85M | 0.77% |
| HEWJ | 0.37% | $347.32M | 0.5% |
| DBE | -0.44% | $50.13M | 0.77% |
| FMHI | -0.51% | $747.15M | 0.7% |
| DXJ | 0.51% | $3.71B | 0.48% |
| SPTS | -0.54% | $5.71B | 0.03% |
| PFFR | -0.55% | $112.85M | 0.45% |
| CXSE | -0.58% | $406.30M | 0.32% |
| LTPZ | -0.58% | $715.65M | 0.2% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| SEIX | -18.95% | $268.81M | 0.62% |
| BTAL | -17.95% | $388.04M | 1.43% |
| BCI | -11.21% | $1.20B | 0.26% |
| SMB | -10.84% | $266.77M | 0.07% |
| CMDY | -10.33% | $279.14M | 0.28% |
| BCD | -10.13% | $245.02M | 0.3% |
| USCI | -8.71% | $185.47M | 1.07% |
| FLRN | -8.63% | $2.33B | 0.15% |
| SOYB | -8.29% | $27.32M | 0.22% |
| CPER | -8.08% | $159.52M | 0.97% |
| IBDQ | -7.82% | $2.89B | 0.1% |
| FLTR | -7.69% | $1.79B | 0.14% |
| TAIL | -7.52% | $67.98M | 0.59% |
| KRBN | -7.48% | $242.47M | 0.85% |
| USTB | -7.33% | $797.28M | 0.35% |
| PWZ | -7.11% | $697.36M | 0.28% |
| CEMB | -7.09% | $435.28M | 0.5% |
| EQLS | -7.02% | $76.08M | 1% |
| VNLA | -7.00% | $2.27B | 0.23% |
| VIXY | -7.00% | $195.31M | 0.85% |
News
Yahoo
WATERTOWN, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an
SeekingAlpha
EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT stock here.
Finnhub
Investor Presentation November 2024 ©2024 EyePoint Pharmaceuticals, Inc. All Rights Reserved. ...
Yahoo
The mean of analysts' price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Yahoo
Baird lowered the firm’s price target on EyePoint (EYPT) to $33 from $38 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results and recapped recent progress, including recently reported, unexpectedly positive, interim data in the Phase 2 VERONA study in DME, and the dosing of the first patient in the pivotal LUGANO study in wet AMD. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Sto
Yahoo
EyePoint Pharmaceuticals ( NASDAQ:EYPT ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.5m (down 31...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.